Drugs / 13C-GSK1322322
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01818011 | Aug → Oct 2013 | bacterial infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13C-GSK1322322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01818011 ↗ |
| Route | Oral | “for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A” NCT01818011 ↗ |